Orexigen Therapeutics (OREX +13.2%) soars again today on the back of the FDA's approval of Arena Pharmaceuticals (ARNA) Belviq weight loss drug. JPMorgan ups the stock to Overweight, saying it "stands to be the biggest beneficiary" as approval for its own weight loss drug, Contrave, is still far off, which leaves a valuation gap with rivals whose drugs are closer to approval.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Wed, 9:36AM)
at Benzinga.com (Jan 14, 2015)
at CNBC.com (Jan 13, 2015)
at Benzinga.com (Jan 12, 2015)
at Benzinga.com (Jan 2, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs